Preference for Domestic Products in the Chinese Market and Market Stagnation Due to the Spread of Infections
First written in FY2023-Q3. 2 of 6 entries say "Worsened", first in FY2025-H1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「In the Diagnostics business, sales of reagents for the PATHFAST mobile immunoassay system and reagents for automated analyzers declined due to lower sales to Russia and a decline in the number of tests conducted in China, among other factors.」
The decline in the number of tests conducted in China continued to be a factor behind lower full-year sales of diagnostic products and reagents. - FY2026-H1WorsenedAnnual report
「In the Diagnostics business, sales of reagents for the PATHFAST mobile immunoassay system and reagents for automated analyzers declined due to lower sales to Russia and a decline in the number of tests conducted in China, among other factors.」
The decline in the number of tests conducted in China continued to be reflected in lower sales of diagnostic products and reagents during the interim period, with the impact of stagnant demand in the Chinese market continuing. - FY2025RestatedAnnual report
「The Biomedica business recorded lower revenue, mainly due to lower demand in Japan, the Americas and China, despite the positive impact of foreign exchange movements and signs of recovery in demand for consumables in some parts of Asia.」
While lower demand in Asia, including China, continued, favorable foreign exchange movements and a recovery in consumables demand in some regions partially offset the impact of the revenue decline. - FY2025-H1WorsenedAnnual report
「Although the Pathology business recorded lower revenue due to sluggish equipment sales amid weak market conditions and lower demand in Asia-Pacific, mainly China, revenue increased overall owing to the favorable impact of foreign exchange movements and strong consumables sales in the Americas and Europe.」
Lower demand in the Asia-Pacific region, mainly in China, was reflected in weak equipment sales in the pathology business. - FY2024-Q1MitigatedAnnual report
「In China, despite the impact of policies favoring domestic products, revenue increased significantly from the same period of the previous year, when Shanghai was under lockdown.」
In China, the impact of policies favoring domestic products remained, but revenue increased significantly from the same period of the previous year, when Shanghai was under lockdown, mitigating the impact of the market stagnation that emerged in the previous period. - FY2023-Q3MaterialisedAnnual report
「In China, we worked to increase sales to offset the impact of the Shanghai lockdown in the first quarter, but revenue declined due to the impact of stronger measures favoring domestic products and market stagnation caused by the spread of COVID-19 infections.」
Although sales-enhancement activities were conducted in China, stronger measures favoring domestic products and market stagnation caused by the spread of COVID-19 were reflected in lower revenue.